Outlook Therapeutics to Present at Two Upcoming Investor Conferences
MONMOUTH JUNCTION, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that of Outlook Therapeutics, will present at two upcoming investor conferences in September.
The following are the details for the conferences.
- Event: Fireside Chat Discussion and Q&A
- Date and Time: Monday, September 14, 2020 at 4:30 PM EDT
- Event: Fireside Chat Discussion and Q&A
- Date and Time: Monday, September 21, 2020 at 2:30 PM EDT
In addition to the presentations, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend either of the conferences.
A live video webcast of the presentations will be accessible on the page of the section of the Outlook Therapeutics website, , approximately two hours after each event and will be archived for 90 days following the event.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway. For more information, please visit .
CONTACTS:
Media Inquiries:
Jessica Morris
Account Executive
LaVoie Health Science
T: 857.701.9731
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
